Becton, Dickinson and Company (BDX) Downgraded by BidaskClub

BidaskClub lowered shares of Becton, Dickinson and Company (NYSE:BDX) from a buy rating to a hold rating in a research report released on Sunday, August 6th.

BDX has been the subject of a number of other research reports. Zacks Investment Research raised Becton, Dickinson and from a hold rating to a buy rating and set a $206.00 target price for the company in a research note on Tuesday, April 11th. Raymond James Financial, Inc. raised Becton, Dickinson and from an outperform rating to a strong-buy rating and lowered their target price for the company from $210.00 to $180.00 in a research note on Friday, June 30th. Bank of America Corporation reissued a buy rating and issued a $225.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Cowen and Company restated an outperform rating and set a $230.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. Finally, Evercore ISI upgraded Becton, Dickinson and from an in-line rating to an outperform rating and boosted their price target for the company from $186.00 to $200.00 in a report on Monday, April 24th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Becton, Dickinson and has a consensus rating of Buy and a consensus price target of $195.79.

Shares of Becton, Dickinson and (NYSE BDX) traded down 0.81% during trading on Friday, reaching $197.69. The company’s stock had a trading volume of 989,225 shares. The stock’s 50-day moving average is $199.72 and its 200-day moving average is $188.69. Becton, Dickinson and has a 12-month low of $161.29 and a 12-month high of $206.63. The stock has a market cap of $44.99 billion, a P/E ratio of 57.25 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same quarter in the previous year, the company posted $2.35 EPS. Becton, Dickinson and’s revenue for the quarter was down 5.1% on a year-over-year basis. Equities research analysts anticipate that Becton, Dickinson and will post $9.46 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was first published by BNB Daily and is the sole property of of BNB Daily. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.baseball-news-blog.com/2017/08/19/becton-dickinson-and-company-bdx-downgraded-by-bidaskclub-updated.html.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be issued a dividend of $0.73 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.48%. Becton, Dickinson and’s dividend payout ratio (DPR) is 83.43%.

In other Becton, Dickinson and news, VP Jeffrey S. Sherman sold 28,765 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the transaction, the vice president now owns 70,821 shares in the company, valued at approximately $13,171,289.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Nabil Shabshab sold 6,149 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $201.76, for a total value of $1,240,622.24. Following the transaction, the insider now owns 15,648 shares in the company, valued at approximately $3,157,140.48. The disclosure for this sale can be found here. Insiders have sold a total of 57,631 shares of company stock worth $11,112,178 in the last quarter. Company insiders own 1.40% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. Oakmont Partners LLC bought a new stake in Becton, Dickinson and during the first quarter valued at $920,000. TNB Financial bought a new stake in Becton, Dickinson and during the first quarter valued at $587,000. First National Bank of Omaha increased its stake in Becton, Dickinson and by 6.7% in the first quarter. First National Bank of Omaha now owns 20,960 shares of the medical instruments supplier’s stock valued at $3,845,000 after buying an additional 1,310 shares during the last quarter. National Pension Service increased its stake in Becton, Dickinson and by 1.6% in the first quarter. National Pension Service now owns 155,231 shares of the medical instruments supplier’s stock valued at $28,517,000 after buying an additional 2,486 shares during the last quarter. Finally, Union Bankshares Corp increased its stake in Becton, Dickinson and by 3.5% in the first quarter. Union Bankshares Corp now owns 21,954 shares of the medical instruments supplier’s stock valued at $4,028,000 after buying an additional 743 shares during the last quarter. Institutional investors own 75.57% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply